Autoantibodies in hospitalised patients with COVID-19.
Eleni Tiniakou, Livia Casciola-Rosen, Mekha A Thomas, Yuka Manabe, Annukka Ar Antar, Mahendra Damarla, Paul M Hassoun, Li Gao, Zitong Wang, Scott Zeger and 1 more
Article in Clinical & translational immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Livia Casciola-RosenDivision of Rheumatology, Department of Medicine Johns Hopkins University School of Medicine Baltimore MD USA.
Mekha A ThomasDivision of Rheumatology, Department of Medicine Johns Hopkins University School of Medicine Baltimore MD USA.
Yuka ManabeDivision of Infectious Diseases, Department of Medicine Johns Hopkins University School of Medicine Baltimore MD USA.
Annukka Ar AntarDivision of Infectious Diseases, Department of Medicine Johns Hopkins University School of Medicine Baltimore MD USA.
Mahendra DamarlaDivision of Pulmonary and Critical Care, Department of Medicine Johns Hopkins University School of Medicine Baltimore MD USA.
Paul M HassounDivision of Pulmonary and Critical Care, Department of Medicine Johns Hopkins University School of Medicine Baltimore MD USA.
Li GaoDivision of Allergy and Immunology, Department of Medicine Johns Hopkins University, School of Medicine Baltimore MD USA.
Zitong WangDepartment of Biostatistics Bloomberg School of Public Health Baltimore MD USA.
Scott ZegerDepartment of Biostatistics Bloomberg School of Public Health Baltimore MD USA.
Antony RosenDivision of Rheumatology, Department of Medicine Johns Hopkins University School of Medicine Baltimore MD USA.
Funding
The Center for Advancing Point of Care in Heart, Lung, Blood and Sleep DiseasesU54HL143541 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BRYAN O BUCHHOLZ, Nathaniel Scott Hafer · 2018 to 2026
$141.0M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
TrainingU54EB007958 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI Matthew Hamill · 2007 to 2026
$34.6M
Sample Processing and Immunoassay Research CoreP30AR070254 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI Antony Rosen · 2016 to 2026
$8.9M
Autoantibodies Define Scleroderma Subgroups with Distinct Relationships to CancerR01AR073208 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI LIVIA A CASCIOLA-ROSEN, Ami Aalok Shah · 2018 to 2026
$5.2M
The HIV Latent Reservoir, Suboptimal Immune Response on Antiretroviral Therapy, and Exogenous Cytokine TherapiesK08AI143391 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ANTAR, ANNUKKA AIDA ROSE · 2019 to 2023
$994k
RNA: Polymerase III specific CD8+ T cells: a mechanistic insight into cancer-induced autoimmunity in sclerodermaK08AR077732 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI TINIAKOU, ELENI · 2021 to 2025
$794k
Prognostic Role of Plasma Xanthine Oxidoreductase in ARDS PatientsR21HL145216 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI GAO, LI, HASSOUN, PAUL M. · 2018 to 2019
Objectives: CD209L and its homologous protein CD209 act as alternative entry receptors for the SARS-CoV-2 virus and are highly expressed in the virally targeted tissues. We tested for the presence and clinical features of autoantibodies targeting these receptors and compared these with autoantibodies known to be associated with COVID-19. Methods: Using banked samples ( Results: Amongst patients hospitalised with COVID-19, 19.5% (23/118) had IgM autoantibodies against CD209L and were more likely to have coronary artery disease (44% vs 19%, Conclusion: We describe IgM autoantibodies against CD209 and CD209L amongst patients hospitalised with COVID-19. These were not associated with disease severity. Conversely, patients with either anti-ACE2 IgM or anti-IFNα IgG antibodies had worse outcomes. Due to the small size of the study cohort, conclusions drawn should be considered cautiously.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Autoantibodies in hospitalised patients with COVID-19. · full record | OpenQuestion